Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sleep Number, Revance, Paysafe, and Organogenesis and Encourages Investors to Contact the Firm

Samstag, 29. Januar 2022 03:00

NEW YORK, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Sleep Number Corporation (NASDAQ: SNBR), Revance Therapeutics, Inc. (NASDAQ: RVNC), Paysafe Limited (NYSE: PSFE), and Organogenesis Holdings, Inc. (NASDAQ: ORGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Sleep Number Corporation (NASDAQ: SNBR)

Class Period: February 18, 2021 – July 20, 2021

Lead Plaintiff Deadline: February 14, 2022

On April 21, 2021, Sleep Number released its first quarter 2021 financial results, missing consensus sales estimates as a result of supply chain disruptions due to Winter Storm Uri in February 2021. Specifically, “more than $50 million of deliveries (two weeks) shifted out of the quarter due to temporary foam supply constraints,” representing nearly 9% of the Company’s entire sales for the quarter.

On this news, Sleep Number’s stock fell $14.80, or 12%, to close at $110.13 per share on April 22, 2021, thereby injuring investors.

Then, on July 20, 2021, Sleep Number released its second quarter 2021 financial results. Once again, the results missed consensus estimates, which the Company blamed on supply constraints and component shortages.

On this news, Sleep Number’s stock fell $14.46, or 12.88%, to close at $97.78 per share on July 21, 2021, thereby injuring investors further.

For more information on the Sleep Number class action go to: https://bespc.com/cases/SNBR

Revance Therapeutics, Inc. (NASDAQ: RVNC)

Class Period: November 25, 2019 – October 11, 2021

Lead Plaintiff Deadline: February 8, 2022

Revance, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The Company’s lead drug candidate is DaxibotulinumtoxinA for injection (“DAXI”), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.

On October 12, 2021, Revance disclosed that on July 2, 2021, the U.S. Food and Drug Administration (“FDA”) had issued a Form 483 notifying Revance of serious issues that the FDA had observed during its inspection of the Company’s Northern California DAXI manufacturing facility. Among other deficiencies, the FDA observed that “[t]he current manufacturing process is not the process proposed for licensure” and Revance’s “Quality Unit lacks the responsibility and authority for the control, review, and approval of outsourced activities[.]” Significantly, the Form 483 only came to light as a result of a Freedom of Information Act (FOIA) request directed to the FDA. On this news, the price of the Company’s shares declined by $6.85 per share, or approximately 25%, from $27.30 per share to close at $20.45 per share on October 12, 2021.

On October 15, 2021, Revance issued a press release announcing that it had received a Complete Response Letter (“CRL”) from the FDA, indicating that the FDA has determined “it is unable to approve the BLA in its present form and indicated that there are deficiencies related to the FDA’s onsite inspection at [Revance’s] manufacturing facility.” On this news, the price of the Company’s shares declined by $8.90 per share, or approximately 39.19%, from $22.71 per share to close at $13.81 per share on October 18, 2021.

The lawsuit alleges throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) quality control deficiencies existed at the Company’s manufacturing facility for DAXI; (ii) the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

For more information on the Revance Therapeutics class action go to: https://bespc.com/cases/RVNC

Paysafe Limited (NYSE: PSFE)

Class Period: December 7, 2020 – November 10, 2021

Lead Plaintiff Deadline: February 8, 2022

On March 30, 2021, Paysafe became a public entity via business combination with FTAC.

Then, on November 11, 2021, before the market opened, Paysafe announced that it was revising its revenue guidance for the full year 2021 downward from a range of $1,530 – $1,550 million to a range of $1,470 – $1,480 million. Paysafe attributed the revision to "[g]ambling regulations and softness in key European markets and performance challenges impacting the Digital Wallet segment" and "[t]he modified scope and timing of new eCommerce customer agreements relative to the Company’s original expectations for these agreements."

On this news, the Company’s share price fell $3.03 per share, or more than 40%, to close at $4.24 per share on November 11, 2021, on unusually heavy trading volume.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that Paysafe was being negatively impacted by gambling regulations in key European markets; (2) that Paysafe was encountering performance challenges in its Digital Wallet segment; (3) that new eCommerce customer agreements were being pushed back; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the Paysafe class action go to: https://bespc.com/cases/PSFE

Organogenesis Holdings, Inc. (NASDAQ: ORGO)

Class Period: March 17, 2021 – October 11, 2021

Lead Plaintiff Deadline: February 8, 2022

On October 12, 2021, Value Investors Club issued a report alleging issues at Organogenesis Holdings, Inc., indicating that the wound care medical company has been improperly billing the federal government for $250 million annually. The Company also set the price for its new wound covering, Affinity, “exorbitantly high,” which Medicare reimbursed, while making the product lucrative for doctors to use through large rebates.

On this news, shares of Organogenesis fell over 18% in intraday trading on October 12, 2021.

For more information on the Organogenesis class action go to: https://bespc.com/cases/ORGO

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

Povezani linkovi: 
Autor:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.